Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Paclitaxel 8Radiotherapy 7Cisplatin 6pembrolizumab 4Fluorouracil 4Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Levoleucovorin 3Leucovorin 3Esophagectomy 3Drug Therapy 3Carboplatin 3lenvatinib 2durvalumab 2Taxes 2TP protocol 2Radiotherapy, Intensity-Modulated 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1palbociclib 1osimertinib 1obinutuzumab 1nedaplatin 1naptumomab estafenatox 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Squamous Cell Carcinoma × Sampling Studies × Clear all
NCT04666090 2025-05-15

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡